Novartis Selects Winter Park for New Radioligand Therapy Manufacturing Facility Press Release
The state-of-the-art, 35,000-square-foot facility represents a major milestone in Novartis’ $23 billion U.S. investment strategy and underscores the Orlando region’s growing reputation as a hub for advanced manufacturing and life sciences innovation.